Find in Library

The purpose of this study was to identify circulating biomarkers of recurrent non-infectious anterior uveitis (NIAU), and to address the anti-inflammatory effects of triglyceride containing docosahexaenoic acid (DHA-TG). A prospective multicenter study was conducted in 72 participants distributed into: patients diagnosed with recurrent NIAU in the quiescence stage (uveitis group (UG); <i>n</i> = 36) and healthy controls (control group (CG); <i>n</i> = 36). Each group was randomly assigned to the oral supplementation of one pill/day (+) containing DHA-TG (<i>n</i> = 18) or no-pill condition (−) (<i>n</i> = 17) for three consecutive months. Data from demographics, risk factors, comorbidities, eye complications and therapy were recorded. Blood was collected and processed to determine pro-inflammatory biomarkers by bead-base multiplex assay. Statistical processing with multivariate statistical analysis was performed. The mean age was 50, 12 (10, 31) years. The distribution by gender was 45% males and 55% females. The mean number of uveitis episodes was 5 (2). Higher plasma expression of interleukin (IL)-6 was detected in the UG versus the CG (<i>p</i> = 5 × 10⁻⁵). Likewise, significantly higher plasma levels were seen for IL-1β, IL-2, INFγ (<i>p</i> = 10⁻⁴), and TNFα (<i>p</i> = 2 × 10⁻⁴) in the UG versus the CG. Significantly lower values of the above molecules were found in the +DHA-TG than in the -DHA-TG subgroups, after 3 months of follow-up, TNFα (<i>p</i> = 10⁻⁷) and IL-6 (<i>p</i> = 3 × 10⁻⁶) being those that most significantly changed. Signatures of circulating inflammatory mediators were obtained in the quiescent stage of recurrent NIAU patients. This 3-month follow-up strongly reinforces that a regular oral administration of DHA-TG reduces the inflammatory load and may potentially supply a prophylaxis-adjunctive mediator for patients at risk of uveitis vision loss.